U.S. FDA Accepts Merck’s Gefapixant New Drug Application for Review

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/18/2026

1. DOO
2. HD
3. ARGX
4. NVDA
5. METC
6. XP
7. SNOW
8. KLAR
9. VNET
10. FN

Go back to U.S. FDA Accepts Merck’s Gefapixant New Drug Application for Review
Merck & Co. (NYSE: MRK) Delayed: 135.97 --0 (-0%)
Previous Close $135.97    52 Week High $65.46 
Open $135.97    52 Week Low $47.97 
Day High $135.97    P/E 92.50 
Day Low $135.97    EPS $1.47 
Volume 6,263